Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Behavioral Neurology & Neuropsychiatry
How do you approach patients considering Leqembi therapy for Alzheimer’s disease who cannot get MRIs?
Answer from: at Community Practice
They are excluded.
Sign In
or
Register
to read more
18249
Related Questions
When do you evaluate patients with Parkinson's disease and cognitive decline for concurrent Alzheimer's disease?
Do you recommend routine neurosyphilis testing in patients being evaluated for dementia?
When is the most appropriate time to initiate evaluation for learning disorders following traumatic brain injury in an adolescent?
When is it useful to test for multiple amyloid-related biomarkers for patients undergoing work-up for cognitive impairment?
How do you treat agitation in progressive supranuclear palsy?
What would be your approach to the consideration of the use of antiamyloid monoclonal antibodies for nonamnestic Alzheimer's disease with a positive biomarker for brain amyloid pathology?
Is there sufficient evidence yet to support the use of lithium supplementation or prescription in the management of neurodegenerative diseases?
What are the limits and standalone value of volumetric MRI for the preclinical evaluation of dementia?
How do stroke-risk considerations affect your use of atypical antipsychotics for patients with dementia?
What patient factors most strongly influence your decision to start biologic agents in mild cognitive impairment?